Literature DB >> 7849320

Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors.

L S Rusten1, S E Jacobsen.   

Abstract

Two tumor necrosis factor receptors (TNFRs) with molecular weights of 55 kD (TNFR-p55) and 75 kD (TNFR-p75) have recently been identified and cloned. In previous studies, TNFR-p55 has been shown to exclusively mediate bidirectional effects of TNF-alpha on committed bone marrow granulocyte-macrophage progenitor cells, whereas both TNFR-p55 and TNFR-p75 can mediate inhibition of primitive progenitors requiring multiple cytokines to proliferate. We show here that TNF-alpha potently and directly inhibits the in vitro growth of committed erythroid progenitor cells in response to multiple cytokine combinations, and that TNF-alpha-induced inhibition of burst-forming unit-erythroid colony formation is mainly mediated through TNFR-p55, although TNFR-p75-mediated inhibition could be observed on progenitors responsive to erythropoietin alone. Moreover, at low TNF-alpha concentrations (2 ng/mL), TNF-alpha stimulates interleukin-3-dependent in vitro growth of committed granulocyte-macrophage progenitor cells, whereas it potently inhibits erythroid progenitor cell proliferation, showing that one concentration of TNF-alpha can simultaneously and bidirectionally modulate interleukin-3-dependent growth of committed granulocyte-macrophage (stimulation) and erythroid progenitor cells (inhibition).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7849320

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model.

Authors:  Gordon A Awandare; Prakasha Kempaiah; Daniel O Ochiel; Paolo Piazza; Christopher C Keller; Douglas J Perkins
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

2.  Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signalling.

Authors:  Jee-Yeong Jeong; Matthew Silver; Aric Parnes; Sarah Nikiforow; Nancy Berliner; Gary J Vanasse
Journal:  Br J Haematol       Date:  2011-07-18       Impact factor: 6.998

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 4.  The therapy of myelofibrosis: targeting pathogenesis.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  Iron status during anti-TNF therapy in children with juvenile idiopathic arthritis.

Authors:  Kristiina Aalto; Visa Honkanen; Pekka Lahdenne
Journal:  Clin Rheumatol       Date:  2010-09-30       Impact factor: 2.980

6.  TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy.

Authors:  Deepika Sharma; Ankit Malik; Clifford Guy; Peter Vogel; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 7.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

8.  Anemia in the elderly.

Authors:  Nancy Berliner
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

9.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Authors:  Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans M Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus.

Authors:  Ling-Yun Sun; Kang-Xin Zhou; Xue-Bing Feng; Hua-Yong Zhang; Xue-Qin Ding; Ou Jin; Li-Wei Lu; Chak-Sing Lau; Ya-Yi Hou; Le-Ming Fan
Journal:  Clin Rheumatol       Date:  2007-04-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.